Immunotherapy in atopic dermatitis.
Immunotherapy
; 14(14): 1149-1164, 2022 10.
Статья
в английский
| MEDLINE | ID: covidwho-2268835
ABSTRACT
In the past decade, the emergence of biologics targeting human cytokine networks has advanced a new era in atopic dermatitis therapy. Dupilumab, in particular, the most widely studied and used IL-4/IL-13 inhibitor, has been considered a milestone in the treatment of patients with moderate-to-severe atopic dermatitis. In addition to the IL-4 and IL-13 pathways, many other cytokines and receptors have been newly targeted as therapeutic options. In this review, the authors provide an overview of the approved and tested biologics and JAK inhibitors for the treatment of atopic dermatitis, including their advantages and limitations.
ключевые слова
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
Biological Products
/
Dermatitis, Atopic
Пределы темы:
Люди
Язык:
английский
Журнал:
Immunotherapy
Тематика журнала:
Аллергология и иммунология
/
Терапия
Год:
2022
Тип:
Статья
Аффилированная страна:
Imt-2022-0054
Документы, близкие по теме
MEDLINE
...
LILACS
LIS